SCHEMBL31014239

SCHEMBL31014239

C1CC(CN[C@@H]2CCCNC2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.44
KDM1A O60341 2/20 0.35
MAOB P27338 1/20 0.35
DPP4 P27487 1/20 0.34
FAP Q12884 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
CCNT1 O60563 2/20 0.33
HRH4 Q9H3N8 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
CPN1 P15169 2/20 0.33
CPB2 Q96IY4 2/20 0.33
EPHX1 P07099 2/20 0.33
MAN1B1 Q9UKM7 1/20 0.33
EED O75530 1/20 0.33
ADH1B P00325 1/20 0.32
ADH1C P00326 1/20 0.32
ADH1A P07327 1/20 0.32
ADH4 P08319 1/20 0.32
ADH7 P40394 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31014227 1.00 KCNH2 (0.44) KCNH2KDM1AMAOBDPP4FAP
SCHEMBL31014224 0.94 KCNH2 (0.45) KCNH2KDM1AMAOBDPP4FAP
Hydrochloric Acid SCHEMBL28866192 0.92 KCNH2 (0.44) KCNH2KDM1AMAOBDPP4FAP
SCHEMBL4635186 0.90 KCNH2 (0.55) KCNH2KDM1AMAOBDPP4FAP
SCHEMBL3812253 0.84 KCNH2 (0.53) KCNH2KDM1AMAOBDPP4FAP
SCHEMBL28063709 0.83 ADH1B (0.37) KCNH2KDM1AMAOBEPHX1MAN1B1
SCHEMBL488706 0.82 KDM1A (0.42) KCNH2KDM1AMAOBHRH4HRH3
SCHEMBL488707 0.82 KDM1A (0.42) KCNH2KDM1AMAOBHRH4HRH3
SCHEMBL6696605 0.82 KDM1A (0.42) KCNH2KDM1AMAOBHRH4HRH3
SCHEMBL17311122 0.81 KCNH2 (0.59) KCNH2KDM1AMAOBDPP4FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US claimed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US claimed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 KCNH2 3247/4885KDM1A 387/4885MAOB 1961/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 KCNH2 3247/4885KDM1A 387/4885MAOB 1961/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 KCNH2 3247/4885KDM1A 387/4885MAOB 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.